Unknown

Dataset Information

0

Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults.


ABSTRACT:

Background

Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) cause respiratory tract illness in children and the elderly. No licensed vaccines are available.

Methods

In this phase 1, randomized, dose-ranging, first-in-human study, the safety, reactogenicity, and humoral immunogenicity of an investigational mRNA-based hMPV and PIV3 combination vaccine, mRNA-1653, were evaluated in healthy adults aged 18-49 years. Sentinel participants (n = 20) received 2 doses of mRNA-1653 (25, 75, 150, or 300 μg) in the dose escalation phase, and participants (n = 104) received 2 doses of mRNA-1653 (75, 150, or 300 μg) or placebo in the dose selection phase; injections were 28 days apart.

Results

The most common solicited reactogenicity events were injection site pain, headache, fatigue, and myalgia, the majority of which were grade 1 or 2. A single mRNA-1653 dose increased neutralization titers against hMPV and PIV3 1 month after vaccination compared with baseline. No notable increases in neutralizing antibody titers were observed with escalating dose levels after mRNA-1653, although no statistical inferences were made; a second mRNA-1653 dose had little observable impact on antibody titers. Neutralizing titers through 1 year remained above baseline for hMPV and returned to baseline for PIV3.

Conclusions

mRNA-1653 was well tolerated, with an acceptable safety profile and increased hMPV and PIV3 neutralization titers in healthy adults.

SUBMITTER: August A 

PROVIDER: S-EPMC9251669 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults.

August Allison A   Shaw Christine A CA   Lee Heather H   Knightly Conor C   Kalidindia Shiva S   Chu Laurence L   Essink Brandon J BJ   Seger William W   Zaks Tal T   Smolenov Igor I   Panther Lori L  

Open forum infectious diseases 20220501 7


<h4>Background</h4>Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) cause respiratory tract illness in children and the elderly. No licensed vaccines are available.<h4>Methods</h4>In this phase 1, randomized, dose-ranging, first-in-human study, the safety, reactogenicity, and humoral immunogenicity of an investigational mRNA-based hMPV and PIV3 combination vaccine, mRNA-1653, were evaluated in healthy adults aged 18-49 years. Sentinel participants (n = 20) received 2 doses of m  ...[more]

Similar Datasets

| S-EPMC7899675 | biostudies-literature
| S-EPMC11420805 | biostudies-literature
| S-EPMC8604720 | biostudies-literature
| S-EPMC7556339 | biostudies-literature
| S-EPMC5478408 | biostudies-literature
| S-EPMC3592345 | biostudies-literature
| S-EPMC2923449 | biostudies-literature
| S-EPMC4080550 | biostudies-literature
| S-EPMC10279702 | biostudies-literature